 |
Endologix Announces First Patient Treated in Ventana(TM) U.S. Clinical Trial
Jan 31, 2012
|
13.0 KB |
|
| |
IRVINE, Calif., Jan. 31, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first patient has been enrolled in the Company's U.S. clinical trial to evaluate the Ventana™ Fenestrated Stent Graft System for the endovascular repair of juxtarenal a...
|
|
Endologix to Present at the 30th Annual J.P. Morgan Healthcare Conference
Jan 3, 2012
|
10.9 KB |
|
| |
IRVINE, Calif., Jan. 3, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisc...
|
|
Endologix to Present at Three Upcoming Investor Conferences
Nov 21, 2011
|
12.0 KB |
|
| |
IRVINE, Calif., Nov. 21, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences and Bob Krist, Chief Financial Officer, is scheduled to presen...
|
|
Endologix to Present at Two Upcoming Conferences
Nov 8, 2011
|
11.5 KB |
|
| |
IRVINE, Calif., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences. The first presentation will be at the Stephens Fall In...
|
|
Endologix Reports 25% Third Quarter 2011 Revenue Growth
Oct 27, 2011
|
26.3 KB |
|
| |
U.S. Revenue Increases by 33%
Raises Revenue Guidance to $82 Million to $84 Million
IRVINE, Calif., Oct. 27, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2011.
...
|
|
Endologix to Report Third Quarter 2011 Financial Results on October 27, 2011
Oct 18, 2011
|
11.4 KB |
|
| |
IRVINE, Calif., Oct. 18, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its third quarter 2011 financial results, which will take place on Thursday, October 27, 2011 after the close of the market.
Endolog...
|
|
Endologix to Present at the Jefferies 2011 Global Healthcare Conference
Sep 22, 2011
|
10.7 KB |
|
| |
IRVINE, Calif., Sept. 22, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that Robert Mitchell, President of Global Strategic Initiatives, is scheduled to present at the Jefferies 2011 Global Healthcare Conference in London.
Event: Je...
|
|
Endologix to Present at Three Upcoming Conferences
Sep 6, 2011
|
11.9 KB |
|
| |
IRVINE, Calif., Sept. 6, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at three upcoming investor conferences. The first presentation will be at the Robert W. Bai...
|
|
Endologix Receives IDE Approval for the Ventana(TM) Fenestrated Stent Graft System
Sep 6, 2011
|
12.8 KB |
|
| |
IRVINE, Calif., Sept. 6, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") conditional approval from the United States Food and Drug Administration ("FDA") to begin U.S. clinical trials to...
|
|
Endologix Appoints Ruth Lyons Vice President of Global Marketing
Aug 30, 2011
|
12.8 KB |
|
| |
IRVINE, Calif., Aug. 30, 2011 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today the appointment of Ruth Lyons to the position of Vice President of Global Marketing. Ms. Lyons brings more than 25 years of marketing and business development experience in th...
|
|
Endologix Announces Favorable Markman Ruling in Cook Patent Litigation
Aug 17, 2011
|
11.3 KB |
|
| |
IRVINE, Calif., Aug. 17, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that Judge Tanya Walton Pratt of the United States District Court for the Southern District of Indiana in Indianapolis has issued a Markman ruling in the ongoing patent infringem...
|
|
Endologix Announces First U.S. Implant of AFX™ Endovascular AAA System
Aug 8, 2011
|
11.7 KB |
|
| |
IRVINE, Calif., Aug. 8, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that the first U.S. commercial implant of the Company's AFX™ Endovascular AAA System was performed at Edward Hines, Jr. VA Hospital in Chicago, IL. The procedure was perform...
|
|
Endologix to Present at Two Upcoming Conferences
Aug 3, 2011
|
11.0 KB |
|
| |
IRVINE, Calif., Aug. 3, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences. The first presentation will be at the 31st Annual Canacc...
|
|
Endologix Reports 22% Second Quarter 2011 Revenue Growth
Jul 21, 2011
|
27.4 KB |
|
| |
IRVINE, Calif., July 21, 2011 /PRNewswire/ -- Endologix, Inc. (NASDAQ: ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2011.
John McDermott, Endologix President and Chief Executive Officer, said, "We are pleased with our progress during the...
|
|
Endologix and LeMaitre Vascular Enter Early Termination Agreement for European Distribution Rights of Endologix Products
Jul 18, 2011
|
14.7 KB |
|
| |
IRVINE, Calif., and BURLINGTON, Mass., July 18, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, and LeMaitre Vascular, Inc. (Nasdaq: LMAT), provider of peripheral vascular devices and implants, announced today that the companies have entered into an early termination...
|
|
Endologix to Report Second Quarter 2011 Financial Results on July 21, 2011
Jul 12, 2011
|
10.0 KB |
|
| |
IRVINE, Calif., July 12, 2011 /PRNewswire/ -- Endologix, Inc. (NASDAQ: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its second quarter 2011 financial results, which will take place on Thursday, July 21, 2011 after the close of the market.
Endologix will ho...
|
|
Endologix Announces FDA Approval of AFX™ Endovascular AAA System
Jun 15, 2011
|
12.3 KB |
|
| |
IRVINE, Calif., June 15, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its next generation product, the AFX™ Endovascular AAA System, for the treatment of abdominal aort...
|
|
Endologix to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
May 6, 2011
|
9.5 KB |
|
| |
IRVINE, Calif., May 6, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 2011 Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV.
Event:
2011 Bank of ...
|
|
Endologix Reports 28% First Quarter 2011 Revenue Growth
Apr 21, 2011
|
19.4 KB |
|
| |
IRVINE, Calif., April 21, 2011 /PRNewswire/ -- Endologix, Inc. (NASDAQ: ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2011.
John McDermott, Endologix President and Chief Executive Officer, said, "First quarter revenue grew by 28% year-over-year...
|
|
Endologix to Report First Quarter 2011 Financial Results on April 21, 2011
Apr 13, 2011
|
10.1 KB |
|
| |
IRVINE, Calif., April 13, 2011 /PRNewswire/ -- Endologix, Inc. (NASDAQ: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its first quarter 2011 financial results, which will take place on Thursday, April 21, 2011 after the close of the market.
Endologix will hold a confere...
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz